Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study

Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab. This retrospective real-life study was conducted in Franc...

Descripción completa

Detalles Bibliográficos
Autores principales: Humbert, Marc, Taillé, Camille, Mala, Laurence, Le Gros, Vincent, Just, Jocelyne, Molimard, Mathieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383600/
https://www.ncbi.nlm.nih.gov/pubmed/29545284
http://dx.doi.org/10.1183/13993003.02523-2017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383600/
https://www.ncbi.nlm.nih.gov/pubmed/29545284
http://dx.doi.org/10.1183/13993003.02523-2017

Ejemplares similares